JP2018531289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531289A5 JP2018531289A5 JP2018541085A JP2018541085A JP2018531289A5 JP 2018531289 A5 JP2018531289 A5 JP 2018531289A5 JP 2018541085 A JP2018541085 A JP 2018541085A JP 2018541085 A JP2018541085 A JP 2018541085A JP 2018531289 A5 JP2018531289 A5 JP 2018531289A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- alkyl
- obesity
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 208000008589 Obesity Diseases 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 235000020824 obesity Nutrition 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- -1 alkyl phosphate Chemical compound 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 150000002825 nitriles Chemical class 0.000 claims description 12
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 150000003568 thioethers Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000008020 Cohen syndrome Diseases 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000012708 MOMO syndrome Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 4
- 208000012696 congenital leptin deficiency Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000002267 hypothalamic effect Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 208000001022 morbid obesity Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000007863 steatosis Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims description 2
- 206010007134 Candida infections Diseases 0.000 claims description 2
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 150000003334 secondary amides Chemical class 0.000 claims description 2
- 150000003511 tertiary amides Chemical class 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 2
- XNDZWMYDZBRUMZ-JSJVQHDDSA-N CC(C)C(N[C@](C)(CC[C@]1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O Chemical compound CC(C)C(N[C@](C)(CC[C@]1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O XNDZWMYDZBRUMZ-JSJVQHDDSA-N 0.000 description 2
- CDDHRXNRAWZSAZ-ZRCCSVPJSA-N CCC(N[C@](C)(CC[C@]1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O Chemical compound CCC(N[C@](C)(CC[C@]1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O CDDHRXNRAWZSAZ-ZRCCSVPJSA-N 0.000 description 2
- URXFSYPKVAKWIZ-WYUYVVTISA-N C[C@@](CC[C@](C)(C1)N(C)C(C)=O)(CC2)[C@@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O Chemical compound C[C@@](CC[C@](C)(C1)N(C)C(C)=O)(CC2)[C@@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O URXFSYPKVAKWIZ-WYUYVVTISA-N 0.000 description 2
- YORMLCBMJXSJIY-KHTMZOKSSA-N C[C@H](C[C@H]([C@@](C)(CC1)C2)[C@](C)(CC[C@]34C)[C@@]1(C)C3=CC=C(C(C)=C1O)C4=CC1=O)C2/[O]=C(/C)\N Chemical compound C[C@H](C[C@H]([C@@](C)(CC1)C2)[C@](C)(CC[C@]34C)[C@@]1(C)C3=CC=C(C(C)=C1O)C4=CC1=O)C2/[O]=C(/C)\N YORMLCBMJXSJIY-KHTMZOKSSA-N 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179997A JP7339992B2 (ja) | 2015-10-23 | 2021-11-04 | セラストロールの類似体 |
| JP2023136867A JP2023164877A (ja) | 2015-10-23 | 2023-08-25 | セラストロールの類似体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245356P | 2015-10-23 | 2015-10-23 | |
| US62/245,356 | 2015-10-23 | ||
| PCT/US2016/058313 WO2017070615A1 (en) | 2015-10-23 | 2016-10-21 | Analogs of celastrol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179997A Division JP7339992B2 (ja) | 2015-10-23 | 2021-11-04 | セラストロールの類似体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531289A JP2018531289A (ja) | 2018-10-25 |
| JP2018531289A6 JP2018531289A6 (ja) | 2018-12-13 |
| JP2018531289A5 true JP2018531289A5 (enExample) | 2019-12-05 |
| JP7034078B2 JP7034078B2 (ja) | 2022-03-11 |
Family
ID=58558149
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541085A Active JP7034078B2 (ja) | 2015-10-23 | 2016-10-21 | セラストロールの類似体 |
| JP2021179997A Active JP7339992B2 (ja) | 2015-10-23 | 2021-11-04 | セラストロールの類似体 |
| JP2023136867A Withdrawn JP2023164877A (ja) | 2015-10-23 | 2023-08-25 | セラストロールの類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179997A Active JP7339992B2 (ja) | 2015-10-23 | 2021-11-04 | セラストロールの類似体 |
| JP2023136867A Withdrawn JP2023164877A (ja) | 2015-10-23 | 2023-08-25 | セラストロールの類似体 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10662218B2 (enExample) |
| EP (1) | EP3364956A4 (enExample) |
| JP (3) | JP7034078B2 (enExample) |
| CN (2) | CN119241632A (enExample) |
| AU (3) | AU2016342375B2 (enExample) |
| BR (1) | BR112018008103A2 (enExample) |
| MA (1) | MA45430A (enExample) |
| WO (1) | WO2017070615A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45430A (fr) | 2015-10-23 | 2019-05-01 | Erx Pharmaceuticals Inc | Analogues de célastrol |
| ES2936226T3 (es) | 2016-04-15 | 2023-03-15 | Beckman Coulter Inc | Macromoléculas fotoactivas y usos de las mismas |
| CN109803664A (zh) * | 2016-06-15 | 2019-05-24 | 尚特·德扎尔基西安 | 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 |
| WO2018006804A1 (zh) * | 2016-07-04 | 2018-01-11 | 厦门大学 | 孤儿核受体Nur77的配体及其用途 |
| CN109705187B (zh) * | 2019-01-29 | 2021-08-20 | 石家庄学院 | 一种雷公藤红素衍生物及其制备方法与应用 |
| CN112094313B (zh) * | 2019-06-17 | 2023-07-04 | 中国科学院上海药物研究所 | 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途 |
| CN112110977B (zh) * | 2019-06-21 | 2022-02-25 | 中国科学院上海药物研究所 | 一类雷公藤红素衍生物、其制备方法及用途 |
| EP4090658A4 (en) | 2020-01-15 | 2024-03-13 | University Of Florida Research Foundation, Incorporated | THERAPEUTIC AGENTS AND METHODS OF TREATMENT |
| CN111202737B (zh) * | 2020-03-20 | 2022-08-05 | 中国药科大学 | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 |
| US20230330237A1 (en) * | 2020-08-28 | 2023-10-19 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| CN115677812B (zh) * | 2022-01-18 | 2023-12-15 | 聊城大学 | 一类雷公藤红素衍生物及其制备方法与应用 |
| US20250375401A1 (en) * | 2022-06-21 | 2025-12-11 | Seoul National University R&Db Foundation | Pharmaceutical composition containing demethylzeylasteral for prevention or treatment of diseases caused by muscle loss |
| AU2023306990A1 (en) * | 2022-07-15 | 2025-01-09 | Celloram Inc. | Celastrol derivatives |
| WO2024108024A1 (en) * | 2022-11-17 | 2024-05-23 | Erx Pharmaceuticals, Inc. | Celastrol salts, crystalline forms, and uses thereof |
| EP4618964A1 (en) * | 2022-11-17 | 2025-09-24 | ERX Pharmaceuticals Inc. | Compositions and methods for treatment of prader-willi syndrome |
| WO2025106760A1 (en) * | 2023-11-16 | 2025-05-22 | Erx Pharmaceuticals Corporation | Intranasal formulations of celastrol |
| CN119431489A (zh) * | 2024-11-13 | 2025-02-14 | 肇源县总医院 | 一种雷公藤红素衍生物及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| FR2875913A1 (fr) | 2004-09-29 | 2006-03-31 | Sea On Line Sa | Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision |
| ES2277568B1 (es) | 2005-12-30 | 2008-04-01 | Consejo Superior De Investigaciones Cientificas | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
| US20110263693A1 (en) | 2006-03-31 | 2011-10-27 | Dana-Farber Cancer Institute, Inc. | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
| US7776894B2 (en) | 2007-08-17 | 2010-08-17 | Burnham Institute For Medical Research | Compositions and methods for inhibiting growth and metastasis of melanoma |
| CN102574890B (zh) * | 2010-08-23 | 2015-03-11 | 苏州润新生物科技有限公司 | 某些化学个体、组合物及方法 |
| BR112014029301A2 (pt) * | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| CN104508233B (zh) | 2012-05-25 | 2017-05-03 | S.P.M.流量控制股份有限公司 | 评估与井口相关联的系统 |
| RU2650646C2 (ru) * | 2012-09-27 | 2018-04-16 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Соединения, предназначенные для лечения ожирения, и способы их применения |
| CA2944030C (en) | 2014-03-26 | 2019-06-04 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
| MA45430A (fr) | 2015-10-23 | 2019-05-01 | Erx Pharmaceuticals Inc | Analogues de célastrol |
| JP7268879B2 (ja) | 2017-01-02 | 2023-05-08 | ガウス サージカル，インコーポレイテッド | 重複撮像を予測した手術アイテムの追跡 |
-
2016
- 2016-10-21 MA MA045430A patent/MA45430A/fr unknown
- 2016-10-21 AU AU2016342375A patent/AU2016342375B2/en active Active
- 2016-10-21 BR BR112018008103-5A patent/BR112018008103A2/pt not_active Application Discontinuation
- 2016-10-21 JP JP2018541085A patent/JP7034078B2/ja active Active
- 2016-10-21 WO PCT/US2016/058313 patent/WO2017070615A1/en not_active Ceased
- 2016-10-21 CN CN202411356905.2A patent/CN119241632A/zh active Pending
- 2016-10-21 US US15/771,077 patent/US10662218B2/en active Active
- 2016-10-21 EP EP16858395.3A patent/EP3364956A4/en active Pending
- 2016-10-21 CN CN201680076127.9A patent/CN108601751A/zh active Pending
-
2020
- 2020-04-15 US US16/849,554 patent/US11753436B2/en active Active
-
2021
- 2021-11-04 JP JP2021179997A patent/JP7339992B2/ja active Active
-
2022
- 2022-06-17 AU AU2022204238A patent/AU2022204238B2/en active Active
-
2023
- 2023-07-17 US US18/353,272 patent/US20240190911A1/en active Pending
- 2023-08-25 JP JP2023136867A patent/JP2023164877A/ja not_active Withdrawn
-
2024
- 2024-03-07 AU AU2024201504A patent/AU2024201504A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531289A5 (enExample) | ||
| EP3181555B1 (en) | Benzothiazole compounds and their pharmaceutical use | |
| JP6553059B2 (ja) | Ｈｂｖ感染の治療のための併用療法 | |
| US10188757B2 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| IL300453A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| JP2020514333A5 (enExample) | ||
| KR101640263B1 (ko) | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 | |
| AU2017254523A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2017526716A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2015509983A5 (enExample) | ||
| CN113490493A (zh) | 治疗脂肪性肝病和/或脂肪性肝炎的方法 | |
| JP2011500621A5 (enExample) | ||
| CN105338975B (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| JP2017513824A5 (enExample) | ||
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| EP3356355A1 (en) | Compounds and combinations for the treatment of hiv | |
| TW202525811A (zh) | 用於治療病毒感染的化合物及方法 | |
| JP2017522304A5 (enExample) | ||
| JP2015531376A5 (enExample) | ||
| JP2016537431A5 (enExample) | ||
| NL1030405C2 (nl) | L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide. | |
| CA2811145A1 (en) | Sesterterpene compound and use thereof | |
| JP2015533128A5 (enExample) |